Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trialPSYCHIATRY RESEARCHIF3.92022-12-016OAAI
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorderBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32022-06-081OA
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current StatusCNS DRUGSIF7.42021-05-1839OAAI
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trialsPSYCHIATRY RESEARCHIF3.92021-02-0122OAAI
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agentsCNS SPECTRUMSIF4.12020-10-3014OAAI
Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and SimulationCLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONSIF2.52020-09-011OAAI
Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescentsCNS SPECTRUMSIF4.12020-03-311OAAI
Cognitive tolerability and health outcomes with once-daily Trokendi XR® (extended-release topiramate) in migraineursJOURNAL OF PAINIF42017-04-010OAAI
Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT)AMERICAN HEART JOURNALIF3.52011-07-017PREAI
A Retrospective, Observational Cohort Analysis of a Nationwide Database to Compare Heart Failure Prescriptions and Related Health Care Utilization Before and After Publication of Updated Treatment Guidelines in the United StatesCLINICAL THERAPEUTICSIF3.62010-08-0118PREAI